Inhibition of PCSK9 Protects against Cerebral Ischemia‒Reperfusion Injury via Attenuating Microcirculatory Dysfunction
- 16 November 2024
- journal article
- research article
- Published by Springer Nature in Neurochemical Research
- Vol. 50 (1) , 1-15
Abstract
Proprotein convertase substilin/kexin type 9 (PCSK9), a pivotal protein regulating lipid metabolism, has been implicated in promoting microthrombotic formation and inflammatory cascades, thereby contributing to cardiovascular ischemia/reperfusion (I/R) injury. However, its involvement in cerebral I/R injury and its potential role in microcirculation protection remain unexplored. In this investigation, we utilized a middle cerebral artery occlusion/reperfusion (MCAO/R) mouse model to simulate ischemic stroke. Different concentrations of evolocumab (1, 5, 10 mg/kg, i.v.), a PCSK9 inhibitor, were administered to assess its impact. Immunofluorescence staining was employed to analyze changes in the expression of occludin, claudin-5, thrombocyte, ICAM-1, VCAM-1, and CD45, providing insights into blood-brain barrier integrity, platelet adhesion, and immune cell infiltration. Moreover, the Morris water maze and elevated plus maze were utilized to evaluate neurological and behavioral functions in MCAO/R mice, shedding light on the effects of PCSK9 inhibition. Our findings revealed a surge in plasma PCSK9 levels post-MCAO/R, peaking at 24 h post-reperfusion. Evolocumab (10 mg/kg) treatment significantly mitigated brain infarction and neurological deficits, evidenced by enhanced locomotor function and reduced post-stroke anxiety. However, it did not ameliorate cognitive impairment following MCAO/R. Additionally, evolocumab administration led to diminished leakage of evans blue solution and upregulated expression of occludin and claudin-5. Thrombocyte, ICAM-1, VCAM-1, and CD45 levels were notably reduced in the penumbral area post-evolocumab treatment. These protective effects are speculated to be mediated through the inhibition of the ERK/NF-κB pathway. The PCSK9 inhibitor evolocumab holds promise as a therapeutic agent during the acute phase of stroke, exerting its beneficial effects by modulating the ERK/NF-κB signaling pathway.Keywords
Funding Information
- National Science Foundation of Jiangsu Province (BK20221553)
- National Natural Science Foundation of China (82001260, 82101245, 82271361)
This publication has 66 references indexed in Scilit:
- Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaqueAtherosclerosis, 2023
- PCSK9 Promotes Endothelial Dysfunction During Sepsis Via the TLR4/MyD88/NF-κB and NLRP3 PathwaysInflammation, 2022
- Novel contact–kinin inhibitor sylvestin targets thromboinflammation and ameliorates ischemic strokeCellular and Molecular Life Sciences, 2022
- PCSK9 acts as a key regulator of Aβ clearance across the blood–brain barrierCellular and Molecular Life Sciences, 2022
- Effect of Intra-arterial Alteplase vs Placebo Following Successful Thrombectomy on Functional Outcomes in Patients With Large Vessel Occlusion Acute Ischemic StrokeJAMA, 2022
- The advances of post-stroke depression: 2021 updateJournal of Neurology, 2021
- PCSK9 regulates pyroptosis via mtDNA damage in chronic myocardial ischemiaBasic Research in Cardiology, 2020
- Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor exerts greater efficacy than atorvastatin on improvement of brain function and cognition in obese ratsArchives of Biochemistry and Biophysics, 2020
- Angiographic Microcirculatory Obstructions Distal to Occlusion Signify Poor Outcome after Endovascular Treatment for Acute Ischemic StrokeTranslational Stroke Research, 2017
- PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signalingCellular and Molecular Life Sciences, 2012